SUBSCRIBE
SUBSCRIBE
News   Drug Development

Johnson & Johnson Prostate Cancer Drug Abiraterone Boosts Survival

September 10, 2010 | 
1 min read
NEW YORK (Reuters) - All patients in a study of a Johnson & Johnson drug for advanced prostate cancer will be offered the medicine after an independent monitoring committee found it demonstrated an improvement in patient survival.
Clinical research Phase III
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
arrow down stock market investment global red technology background. Global economic slowdown and crisis. vector illustration fantastic technology.
RNA editing
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
November 13, 2025
 · 
3 min read
 · 
Annalee Armstrong
The factor that changes everything. A critical break. A sudden change in plans. A threat and a danger. Recover from the blow and get back on course. Severe stress. Withstand the blow.
Obesity
Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs
November 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage image sketch of tired girl sleeping home nightmare monster in room isolated on drawing background.
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
November 13, 2025
 · 
2 min read
 · 
Tristan Manalac